242 related articles for article (PubMed ID: 35047111)
21. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study.
Correll CU; Koblan KS; Hopkins SC; Li Y; Heather Dworak ; Goldman R; Loebel A
NPJ Schizophr; 2021 Dec; 7(1):63. PubMed ID: 34887427
[TBL] [Abstract][Full Text] [Related]
22. Potential of Ligands for Trace Amine-Associated Receptor 1 (TAAR1) in the Management of Substance Use Disorders.
Wu R; Li JX
CNS Drugs; 2021 Dec; 35(12):1239-1248. PubMed ID: 34766253
[TBL] [Abstract][Full Text] [Related]
23. A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
Kane JM
J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5 Suppl 1):S1-S13. PubMed ID: 36099402
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of OCT2-mediated drug-drug interactions between ulotaront and metformin in subjects with schizophrenia.
Xiao G; Tsukada H; Chen YL; Shi L; Hopkins SC; Galluppi GR
Pharmacol Res Perspect; 2024 Apr; 12(2):e1191. PubMed ID: 38527949
[TBL] [Abstract][Full Text] [Related]
25. Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine.
Revel FG; Meyer CA; Bradaia A; Jeanneau K; Calcagno E; André CB; Haenggi M; Miss MT; Galley G; Norcross RD; Invernizzi RW; Wettstein JG; Moreau JL; Hoener MC
Neuropsychopharmacology; 2012 Nov; 37(12):2580-92. PubMed ID: 22763617
[TBL] [Abstract][Full Text] [Related]
26. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.
Revel FG; Moreau JL; Gainetdinov RR; Bradaia A; Sotnikova TD; Mory R; Durkin S; Zbinden KG; Norcross R; Meyer CA; Metzler V; Chaboz S; Ozmen L; Trube G; Pouzet B; Bettler B; Caron MG; Wettstein JG; Hoener MC
Proc Natl Acad Sci U S A; 2011 May; 108(20):8485-90. PubMed ID: 21525407
[TBL] [Abstract][Full Text] [Related]
27. Structural and signaling mechanisms of TAAR1 enabled preferential agonist design.
Shang P; Rong N; Jiang JJ; Cheng J; Zhang MH; Kang D; Qi L; Guo L; Yang GM; Liu Q; Zhou Z; Li XB; Zhu KK; Meng QB; Han X; Yan W; Kong Y; Yang L; Wang X; Lei D; Feng X; Liu X; Yu X; Wang Y; Li Q; Shao ZH; Yang F; Sun JP
Cell; 2023 Nov; 186(24):5347-5362.e24. PubMed ID: 37963465
[TBL] [Abstract][Full Text] [Related]
28. Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.
Perini F; Nazimek JM; Mckie S; Capitão LP; Scaife J; Pal D; Browning M; Dawson GR; Nishikawa H; Campbell U; Hopkins SC; Loebel A; Elliott R; Harmer CJ; Deakin B; Koblan KS
Schizophrenia (Heidelb); 2023 Aug; 9(1):49. PubMed ID: 37550314
[TBL] [Abstract][Full Text] [Related]
29. Trace Amine-Associated Receptor 1 Agonist Modulates Mismatch Negativity-Like Responses in Mice.
Aleksandrov AA; Knyazeva VM; Volnova AB; Dmitrieva ES; Polyakova NV; Gainetdinov RR
Front Pharmacol; 2019; 10():470. PubMed ID: 31130864
[TBL] [Abstract][Full Text] [Related]
30. Deletion of Trace Amine-Associated Receptor 1 Attenuates Behavioral Responses to Caffeine.
Schwartz MD; Palmerston JB; Lee DL; Hoener MC; Kilduff TS
Front Pharmacol; 2018; 9():35. PubMed ID: 29456505
[TBL] [Abstract][Full Text] [Related]
31. Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT
Isaacson SH; Goldstein M; Pahwa R; Singer C; Klos K; Pucci M; Zhang Y; Crandall D; Koblan KS; Navia B;
Neurol Clin Pract; 2023 Aug; 13(4):e200175. PubMed ID: 37273942
[TBL] [Abstract][Full Text] [Related]
32. Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term.
Blum K; Badgaiyan RD; Braverman ER; Dushaj K; Li M; Thanos PK; Demetrovics Z; Febo M
J Reward Defic Syndr Addict Sci; 2016; 2(1):14-21. PubMed ID: 28317038
[TBL] [Abstract][Full Text] [Related]
33. Recognition of methamphetamine and other amines by trace amine receptor TAAR1.
Liu H; Zheng Y; Wang Y; Wang Y; He X; Xu P; Huang S; Yuan Q; Zhang X; Wang L; Jiang K; Chen H; Li Z; Liu W; Wang S; Xu HE; Xu F
Nature; 2023 Dec; 624(7992):663-671. PubMed ID: 37935377
[TBL] [Abstract][Full Text] [Related]
34. Trace amine-associated receptor 1 as a monoaminergic modulator in brain.
Xie Z; Miller GM
Biochem Pharmacol; 2009 Nov; 78(9):1095-104. PubMed ID: 19482011
[TBL] [Abstract][Full Text] [Related]
35. Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors.
Leo D; Mus L; Espinoza S; Hoener MC; Sotnikova TD; Gainetdinov RR
Neuropharmacology; 2014 Jun; 81():283-91. PubMed ID: 24565640
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia.
Galluppi GR; Polhamus DG; Fisher JM; Hopkins SC; Koblan KS
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1245-1254. PubMed ID: 34292664
[TBL] [Abstract][Full Text] [Related]
37. The Trace Amine-Associated Receptor 1 Agonist 3-Iodothyronamine Induces Biased Signaling at the Serotonin 1b Receptor.
Bräunig J; Dinter J; Höfig CS; Paisdzior S; Szczepek M; Scheerer P; Rosowski M; Mittag J; Kleinau G; Biebermann H
Front Pharmacol; 2018; 9():222. PubMed ID: 29593543
[TBL] [Abstract][Full Text] [Related]
38. [An antipsychotic without dopamine receptor blockade?].
Spoelstra SK; Bruggeman R; Knegtering H
Tijdschr Psychiatr; 2021; 63(11):804-809. PubMed ID: 34851520
[TBL] [Abstract][Full Text] [Related]
39. TAARs as Novel Therapeutic Targets for the Treatment of Depression: A Narrative Review of the Interconnection with Monoamines and Adult Neurogenesis.
Shemiakova TS; Efimova EV; Gainetdinov RR
Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927470
[TBL] [Abstract][Full Text] [Related]
40. Biological evaluation and
Wang Y; Liu Z; Lu J; Wang W; Wang L; Yang Y; Wang H; Ye L; Zhang J; Tian J
Front Pharmacol; 2023; 14():1161964. PubMed ID: 37153799
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
